Investors

Global Links


Management Team

Investors

Press Releases

DateSubject
December 22, 2004 Cerus Acquires Additional Rights to Mesothelin Cancer Antigen from Chugai Pharmaceutical
December 20, 2004 Cerus Corporation Announces Transition of John Hearst
December 3, 2004 Cerus Corporation and Collaborators to Present at American Society of Hematology Meeting
November 9, 2004 Cerus Corporation Announces Third Quarter Results
October 26, 2004 Cerus Corporation to Webcast Third Quarter Financial Results Conference Call
October 22, 2004 Cerus Corporation to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference
October 14, 2004 Baxter and Cerus Announce Closure of Transaction with BioOne Corporation
September 22, 2004 Preclinical Results Demonstrate Potential Therapeutic and Safety Benefits of Cerus' Cancer Immunotherapy Technology
July 29, 2004 Baxter and Cerus Enter Agreement with Asian Partner for Commercialization of INTERCEPT Blood System for Platelets
July 29, 2004 Cerus Corporation Announces Second Quarter Results
July 28, 2004 Cerus Appoints William J. Dawson as Vice President, Finance and Chief Financial Officer
July 28, 2004 Cerus Awarded NIH Grant to Develop Anthrax Vaccine
July 22, 2004 Cerus Corporation Invites You to Join a Webcast of its Second Quarter Financial Results Conference Call
June 30, 2004 Cerus Increases Development Focus on Therapeutic Vaccines
June 14, 2004 Cerus Reports Initial Results from Additional Analysis of the U.S. Phase III Data for the INTERCEPT Blood System for Platelets
May 19, 2004 Cerus Reports Phase III Results for the INTERCEPT Plasma System
May 3, 2004 Cerus Appoints Claes Glassell As President And Chief Executive Officer
May 3, 2004 Cerus Corporation Announces First Quarter Results
April 28, 2004 Cerus Announces Scientific Advisory Board for Therapeutic Vaccine Development
April 26, 2004 Cerus Corporation Invites You to Join a Webcast of its First Quarter Financial Results Conference Call
April 21, 2004 MedImmune and Cerus Enter Agreement to Co-Develop Therapeutic Vaccine for Cancer
January 29, 2004 Cerus Corporation Announces Fourth Quarter And Year-End Results
January 28, 2004 Cerus Corporation Acquires Rights to Cancer Antigen and Receives Phase I SBIR Grant
January 26, 2004 Cerus Corporation Invites You to Join a Webcast of its Fourth Quarter and Year End Financial Results Conference Call